+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hepatitis Therapeutics Market by Therapeutic Class (Combination Therapies, Direct Acting Antivirals, Interferons), Genotype (Genotype 1, Genotype 2, Genotype 3), Route Of Administration, Distribution Channel, Stage Of Disease - Global Forecast 2025-2030- Product Image
Hepatitis Therapeutics Market by Therapeutic Class (Combination Therapies, Direct Acting Antivirals, Interferons), Genotype (Genotype 1, Genotype 2, Genotype 3), Route Of Administration, Distribution Channel, Stage Of Disease - Global Forecast 2025-2030- Product Image
Sale

Hepatitis Therapeutics Market by Therapeutic Class (Combination Therapies, Direct Acting Antivirals, Interferons), Genotype (Genotype 1, Genotype 2, Genotype 3), Route Of Administration, Distribution Channel, Stage Of Disease - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715892
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hepatitis Therapeutics Market is undergoing rapid transformation, propelled by advancements in drug development, evolving healthcare delivery models, and intensified stakeholder collaboration.

Market Snapshot: Hepatitis Therapeutics Market Overview

The global Hepatitis Therapeutics Market grew from USD 30.76 billion in 2024 to USD 32.02 billion in 2025. Continued expansion is anticipated at a CAGR of 3.90%, projecting market value to reach USD 38.72 billion by 2030. This growth reflects strong demand for innovative therapies and strategic responses to complex public health needs.

Scope & Segmentation

This report delivers comprehensive insights into therapeutic classes, patient types, delivery technologies, and market distribution, supporting informed strategic planning and investment decisions.

  • Therapeutic Class: Combination therapies, direct acting antivirals, interferons, and nucleotide analogues, including categories such as NS3/4A protease inhibitors, NS5A inhibitors, NS5B polymerase inhibitors, and pan-genotypic regimens.
  • Genotype: Genotype 1 (subtypes 1A and 1B), Genotype 2, Genotype 3, Genotype 4, Genotype 5, and Genotype 6.
  • Route of Administration: Injectable (intravenous and subcutaneous) and oral formats, addressing varied patient preferences and pharmacokinetic requirements.
  • Distribution Channel: Hospital pharmacies, online pharmacies, retail pharmacies—enabling broad patient access and supplemental services supporting therapy adherence.
  • Stage of Disease: Acute and chronic hepatitis conditions guide therapeutic approaches and monitoring protocols.
  • Region: Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East and Africa (such as United Kingdom, Germany, France, UAE, Nigeria, and others), and Asia-Pacific (including China, India, Japan, Australia, and others).
  • Key Companies: Gilead Sciences, AbbVie, Merck & Co., Bristol-Myers Squibb, Johnson & Johnson, F. Hoffmann-La Roche, Novartis, Pfizer, GlaxoSmithKline, Sanofi.

Key Takeaways for Senior Decision Makers

  • Recent advances in direct acting antivirals enable more effective and tolerable patient regimens, supporting clinical outcome improvements and operational efficiencies.
  • Combination therapies and pan-genotypic regimens are shifting product development and driving new clinical pathway strategies, especially in populations with resistance concerns.
  • Digital health platforms now play a pivotal role in real-time therapy monitoring, supporting adherence and safety tracking among diverse patient groups.
  • Biosimilars and generics are intensifying pricing competition, motivating innovators to enhance value via real-world evidence and patient-reported outcomes.
  • Regional differences in healthcare infrastructure, diagnosis capabilities, and payer models require adaptable market access and engagement strategies.
  • Stakeholders are leveraging partnerships and licensing arrangements to accelerate market entry, broaden distribution, and expand access in underserved regions.

Tariff Impact: U.S. 2025 Tariff Adjustments

U.S. tariff revisions in 2025 will influence supply chain cost structures and pricing. Manufacturers sourcing active ingredients and packaging internationally may encounter increased input costs, possibly prompting shifts in production location. Health system payers may respond with stricter formulary controls, while advocacy groups push for expanded patient support to counter potential affordability challenges. These changes could also incentivize domestic manufacturing and support greater supply chain resilience if companies align operations with new trade requirements.

Methodology & Data Sources

This report draws upon robust primary and secondary research, including expert interviews, real-world market intelligence, regulatory reviews, and financial filings. Rigorous triangulation and validation ensure credible, actionable insights across all market segments analyzed.

Why This Report Matters

  • Enables confident strategic planning by illuminating emerging treatment modalities and evolving market access dynamics in the hepatitis therapeutics space.
  • Supports decision-makers in identifying key growth opportunities, risk mitigation measures, and partnership models crucial for sustainable competitiveness.
  • Equips stakeholders with segmented, actionable intelligence for optimized product development and targeted investment prioritization.

Conclusion

The Hepatitis Therapeutics Market is shaped by scientific advances, shifting regulatory and tariff landscapes, and regional disparities. Informed, adaptive strategies are essential for harnessing innovation, improving patient access, and achieving long-term growth within this dynamic sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging real-world efficacy data on pan-genotypic direct-acting antivirals in treating hepatitis C patients
5.2. Adoption of long-acting injectable therapies for chronic hepatitis B management in underserved populations
5.3. Development of host-targeted therapeutic strategies aiming for functional cure in chronic hepatitis B patients
5.4. Increased market penetration of generic direct-acting antivirals driving price competition and access improvements
5.5. Integration of telemedicine platforms to optimize monitoring and adherence in hepatitis treatment protocols
5.6. Advancements in viral vector vaccine research targeting hepatitis E for outbreak prevention in developing regions
5.7. Progress in immunotherapy regimens combining checkpoint inhibitors with antivirals for hepatitis D coinfection
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hepatitis Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. Combination Therapies
8.3. Direct Acting Antivirals
8.3.1. Ns3/4A Protease Inhibitors
8.3.2. Ns5A Inhibitors
8.3.3. Ns5B Polymerase Inhibitors
8.3.4. Pan Genotypic Regimens
8.4. Interferons
8.5. Nucleotide Analogues
9. Hepatitis Therapeutics Market, by Genotype
9.1. Introduction
9.2. Genotype 1
9.2.1. Genotype 1A
9.2.2. Genotype 1B
9.3. Genotype 2
9.4. Genotype 3
9.5. Genotype 4
9.6. Genotype 5
9.7. Genotype 6
10. Hepatitis Therapeutics Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous
10.2.2. Subcutaneous
10.3. Oral
11. Hepatitis Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Hepatitis Therapeutics Market, by Stage Of Disease
12.1. Introduction
12.2. Acute
12.3. Chronic
13. Americas Hepatitis Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Hepatitis Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Hepatitis Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Gilead Sciences, Inc.
16.3.2. AbbVie Inc.
16.3.3. Merck & Co., Inc.
16.3.4. Bristol-Myers Squibb Company
16.3.5. Johnson & Johnson
16.3.6. F. Hoffmann-La Roche Ltd
16.3.7. Novartis AG
16.3.8. Pfizer Inc.
16.3.9. GlaxoSmithKline plc
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HEPATITIS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HEPATITIS THERAPEUTICS MARKET: RESEARCHAI
FIGURE 26. HEPATITIS THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 27. HEPATITIS THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 28. HEPATITIS THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HEPATITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 111. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 112. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 113. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 114. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 115. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 116. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 117. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 118. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 119. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 122. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 123. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 126. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 127. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 130. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 131. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 132. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 134. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 135. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 138. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 139. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 142. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 209. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 212. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 213. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 214. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 215. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 216. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 217. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 220. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 221. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 224. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 225. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 228. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 229. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 230. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 231. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 232. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 233. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 236. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 237. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 240. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 257. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 258. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 259. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 260. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 261. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 262. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 263. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 264. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 265. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 268. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 269. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 272. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 273. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 275. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 276. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 277. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 278. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 279. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 280. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 281. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 284. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 285. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 288. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 316. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2024 (USD MILLION)
TABLE 320. SAUDI ARABIA HE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hepatitis Therapeutics market report include:
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 32.02 Billion
Forecasted Market Value ( USD ) by 2030 $ 38.72 Billion
Compound Annual Growth Rate3.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hepatitis Therapeutics - Global Strategic Business Report - Product Image

Hepatitis Therapeutics - Global Strategic Business Report

  • Report
  • 298 Pages
  • Global
From
Antiviral Drugs Market by Indication (Hepatitis B, Hepatitis C, Herpes Simplex), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Non Nucleoside Reverse Transcriptase Inhibitors), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Antiviral Drugs Market by Indication (Hepatitis B, Hepatitis C, Herpes Simplex), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Non Nucleoside Reverse Transcriptase Inhibitors), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Hepatitis C Market Report 2025 - Product Image

Hepatitis C Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Direct-acting Antiviral Drug Market by Product Type (Branded Drugs, Generic Drugs), Therapeutic Class (Combination Therapy, Ns5A Inhibitor, Ns5B Inhibitor), Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Direct-acting Antiviral Drug Market by Product Type (Branded Drugs, Generic Drugs), Therapeutic Class (Combination Therapy, Ns5A Inhibitor, Ns5B Inhibitor), Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Hepatitis Therapeutics Market Report 2025 - Product Image

Hepatitis Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Hepatitis Drug Market

The Hepatitis Drug market is a subset of the Infectious Diseases Drugs market, which includes treatments for a variety of illnesses caused by microorganisms. Hepatitis drugs are used to treat viral infections of the liver, including hepatitis A, B, and C. These drugs can be used to reduce symptoms, prevent further damage to the liver, and even cure the infection. Common treatments include antiviral medications, interferon, and direct-acting antivirals. The Hepatitis Drug market is highly competitive, with many companies offering treatments for different types of hepatitis. Some of the major players in the market include AbbVie, Gilead Sciences, Merck, Bristol-Myers Squibb, and Novartis. Other companies such as Cipla, Mylan, and Teva Pharmaceuticals also offer treatments for hepatitis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.